Cardiac Safety in the APHINITY trial

Cardiac Safety in the APHINITY trial

OVERVIEW ESMO Open has published an article co-authored by a member of our Biostatistics team. Results of the exploratory analysis conclude that after >6 years of median follow-up, pertuzumab and trastuzumab did not increase cardiotoxicity risk compared to...
Overall survival in the OlympiA trial

Overall survival in the OlympiA trial

OVERVIEW OlympiA demonstrates statistically significant improvement in overall survival with adjuvant olaparib compared with placebo TITLE OF PUBLICATION Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants...
Overall survival in the OlympiA trial

APHINITY | Annals of Oncology

Title of Publication Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years’ follow-up AUTHORS Loibl, S; Jassem, J; Sonnenblick, A; Parlier, D; Winer, E; Bergh, J; Gelber, RD; Restuccia, E; Im, YH; Huang,...